Log in

Nektar Therapeutics News Headlines (NASDAQ:NKTR)

$20.34
-0.64 (-3.05 %)
(As of 11/13/2019 08:14 AM ET)
Today's Range
$20.28
Now: $20.34
$21.34
50-Day Range
$15.99
MA: $17.90
$20.48
52-Week Range
$15.64
Now: $20.34
$47.11
Volume3.22 million shs
Average Volume2.39 million shs
Market Capitalization$3.57 billion
P/E Ratio5.38
Dividend YieldN/A
Beta2.62

Headlines

Nektar Therapeutics (NASDAQ NKTR) News Headlines

Source:
DateHeadline
Why This Early-Stage Autoimmune and Chronic Inflamatory Trial May Be a Big HitWhy This Early-Stage Autoimmune and Chronic Inflamatory Trial May Be a Big Hit
247wallst.com - November 12 at 2:32 PM
Nektar Therapeutics (NASDAQ:NKTR) Rating Reiterated by Canaccord GenuityNektar Therapeutics (NASDAQ:NKTR) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - November 12 at 7:36 AM
Comparing Calithera Biosciences (NASDAQ:CALA) & Nektar Therapeutics (NASDAQ:NKTR)Comparing Calithera Biosciences (NASDAQ:CALA) & Nektar Therapeutics (NASDAQ:NKTR)
www.americanbankingnews.com - November 11 at 11:41 PM
Nektar Therapeutics (NKTR) Presents At 34th Annual Meeting of SITC -Nektar Therapeutics (NKTR) Presents At 34th Annual Meeting of SITC -
seekingalpha.com - November 11 at 5:58 PM
Nektar Therapeutics (NASDAQ:NKTR) Earns "Neutral" Rating from HC WainwrightNektar Therapeutics (NASDAQ:NKTR) Earns "Neutral" Rating from HC Wainwright
www.americanbankingnews.com - November 11 at 1:14 PM
Why This Early-Stage Autoimmune and Chonic Inflamatory Trial May Be a Big HitWhy This Early-Stage Autoimmune and Chonic Inflamatory Trial May Be a Big Hit
www.msn.com - November 11 at 12:57 PM
Nektar Hikes on Study FindingsNektar Hikes on Study Findings
www.marketwatch.com - November 11 at 12:57 PM
Nektar up 5% premarket on encouraging NKTR-358 dataNektar up 5% premarket on encouraging NKTR-358 data
seekingalpha.com - November 11 at 12:57 PM
Nektar Therapeutics Stock Is Rising on Test Data for Cancer DrugNektar Therapeutics Stock Is Rising on Test Data for Cancer Drug
finance.yahoo.com - November 11 at 12:57 PM
Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug?Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug?
finance.yahoo.com - November 11 at 12:57 PM
FY2019 EPS Estimates for Nektar Therapeutics (NASDAQ:NKTR) Boosted by Piper Jaffray CompaniesFY2019 EPS Estimates for Nektar Therapeutics (NASDAQ:NKTR) Boosted by Piper Jaffray Companies
www.americanbankingnews.com - November 11 at 2:55 AM
FY2019 EPS Estimates for Nektar Therapeutics Increased by William Blair (NASDAQ:NKTR)FY2019 EPS Estimates for Nektar Therapeutics Increased by William Blair (NASDAQ:NKTR)
www.americanbankingnews.com - November 11 at 2:52 AM
Research Analysts Offer Predictions for Nektar Therapeutics FY2019 Earnings (NASDAQ:NKTR)Research Analysts Offer Predictions for Nektar Therapeutics' FY2019 Earnings (NASDAQ:NKTR)
www.americanbankingnews.com - November 11 at 2:52 AM
Nektar Therapeutics Presents Data from First-in-...Nektar Therapeutics Presents Data from First-in-...
www.benzinga.com - November 10 at 2:48 PM
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of RheumatologyNektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
www.prnewswire.com - November 10 at 12:18 PM
BRIEF-Nektar Therapeutics Presents New Clinical And Preclinical Data From Its Immuno-Oncology PipelineBRIEF-Nektar Therapeutics Presents New Clinical And Preclinical Data From Its Immuno-Oncology Pipeline
www.msn.com - November 10 at 9:47 AM
Nektar Therapeutics Presents New Clinical and...Nektar Therapeutics Presents New Clinical and...
www.benzinga.com - November 9 at 10:26 PM
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual MeetingNektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 9 at 10:26 PM
Nektar Therapeutics Forecasted to Post Q1 2021 Earnings of ($0.65) Per Share (NASDAQ:NKTR)Nektar Therapeutics Forecasted to Post Q1 2021 Earnings of ($0.65) Per Share (NASDAQ:NKTR)
www.americanbankingnews.com - November 8 at 10:31 PM
Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Hold" from AnalystsNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 8 at 5:38 AM
Interesting NKTR Put And Call Options For December 27thInteresting NKTR Put And Call Options For December 27th
www.nasdaq.com - November 8 at 12:36 AM
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock UpNektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
finance.yahoo.com - November 7 at 7:36 PM
Nektar Therapeutics (NASDAQ:NKTR) Price Target Lowered to $35.00 at Piper Jaffray CompaniesNektar Therapeutics (NASDAQ:NKTR) Price Target Lowered to $35.00 at Piper Jaffray Companies
www.americanbankingnews.com - November 7 at 5:37 PM
Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from CowenNektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from Cowen
www.americanbankingnews.com - November 7 at 10:51 AM
How Sweet Were Nektar Therapeutics Q3 Results?How Sweet Were Nektar Therapeutics' Q3 Results?
www.fool.com - November 7 at 9:35 AM
Edited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMTEdited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMT
finance.yahoo.com - November 7 at 9:35 AM
Mizuho Reaffirms Hold Rating for Nektar Therapeutics (NASDAQ:NKTR)Mizuho Reaffirms Hold Rating for Nektar Therapeutics (NASDAQ:NKTR)
www.americanbankingnews.com - November 7 at 7:05 AM
Nektar Therapeutics (NKTR) Q3 2019 Earnings Call TranscriptNektar Therapeutics (NKTR) Q3 2019 Earnings Call Transcript
www.fool.com - November 7 at 1:13 AM
Nektar Therapeutics (NASDAQ:NKTR) Posts Quarterly  Earnings Results, Beats Estimates By $0.17 EPSNektar Therapeutics (NASDAQ:NKTR) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS
www.americanbankingnews.com - November 6 at 9:05 PM
Nektar Therapeutics EPS beats by $0.17, beats on revenueNektar Therapeutics EPS beats by $0.17, beats on revenue
seekingalpha.com - November 6 at 5:17 PM
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
finance.yahoo.com - November 6 at 5:17 PM
Nektar Therapeutics Q3 2019 Earnings PreviewNektar Therapeutics Q3 2019 Earnings Preview
seekingalpha.com - November 5 at 8:59 PM
Immunotherapy Drug Pairings Revitalizing the Fight Against CancerImmunotherapy Drug Pairings Revitalizing the Fight Against Cancer
www.baystreet.ca - November 5 at 10:57 AM
Zacks: Brokerages Anticipate Nektar Therapeutics (NASDAQ:NKTR) Will Post Quarterly Sales of $26.21 MillionZacks: Brokerages Anticipate Nektar Therapeutics (NASDAQ:NKTR) Will Post Quarterly Sales of $26.21 Million
www.americanbankingnews.com - November 5 at 4:38 AM
-$0.73 Earnings Per Share Expected for Nektar Therapeutics (NASDAQ:NKTR) This Quarter-$0.73 Earnings Per Share Expected for Nektar Therapeutics (NASDAQ:NKTR) This Quarter
www.americanbankingnews.com - November 3 at 1:13 AM
Nektar Therapeutics (NKTR) to Release Quarterly Earnings on WednesdayNektar Therapeutics (NKTR) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 12:25 PM
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual MeetingNektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
finance.yahoo.com - November 1 at 9:38 AM
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial MarketsNektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
finance.yahoo.com - October 30 at 7:29 PM
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - October 30 at 2:28 PM
Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ?Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ?
finance.yahoo.com - October 29 at 2:57 AM
Nektar Therapeutics (NASDAQ:NKTR) Forecasted to Post Q3 2019 Earnings of ($0.65) Per ShareNektar Therapeutics (NASDAQ:NKTR) Forecasted to Post Q3 2019 Earnings of ($0.65) Per Share
www.americanbankingnews.com - October 28 at 1:12 AM
With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime"With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime"
finance.yahoo.com - October 25 at 6:09 PM
With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime"With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime"
finance.yahoo.com - October 25 at 6:09 PM
How Bempegaldesleukin Woes Have Impacted Nektar TherapeuticsHow Bempegaldesleukin Woes Have Impacted Nektar Therapeutics
www.nasdaq.com - October 24 at 1:15 PM
Oppenheimer Begins Coverage on Nektar Therapeutics (NASDAQ:NKTR)Oppenheimer Begins Coverage on Nektar Therapeutics (NASDAQ:NKTR)
www.americanbankingnews.com - October 24 at 8:13 AM
Nektar Therapeutics (NASDAQ:NKTR) Major Shareholder Katharina Otto-Bernstein Sells 29,127 SharesNektar Therapeutics (NASDAQ:NKTR) Major Shareholder Katharina Otto-Bernstein Sells 29,127 Shares
www.americanbankingnews.com - October 22 at 8:53 AM
FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019
finance.yahoo.com - October 18 at 2:06 PM
KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors - NKTRKESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors - NKTR
www.marketwatch.com - October 17 at 12:29 PM
FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar TherapeuticsFINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
finance.yahoo.com - October 16 at 7:07 PM
Nektar launches early-stage study of NKTR-255 in blood cancerNektar launches early-stage study of NKTR-255 in blood cancer
seekingalpha.com - October 16 at 2:07 PM
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Trading on Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel